/Investor DB

YK Bioventures — 2025 Investments

5 investments dated 2025 · listed companies and verified rows first · show all

Shenandoah Therapeutics Inc.inMay 2025SEC filingmedium confidence

South San Francisco, US

Mark Stepka(Executive Officer)inIsabella Graef(Executive Officer, Director)Nathanael Gray(Director)

BoardWendy Young(Director)Jim Edwards(Director)

Board seatGary Yeung· per SEC Form D · $21.5M raise · filed May 2025

Neurona Therapeuticsneuronatherapeutics.cominApr 2025 · $102M

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.

BiotechDeep TechHealthtechSouth San Francisco, US

Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)

Co-investorsBerkeley FrontierIaso VenturesLYFE CapitalThe Column GroupViking GlobalYsios Capital+8 more

Normunitynormunity.comin𝕏Jan 2025

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)

Co-investorsEnavate SciencesSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan Partners+7 more

Pelagepelagepharma.comin𝕏Oct 2025

Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.

BiotechHealthtechLongevityLos Angeles, US

Heather Christofk(Executive Officer)William Lowry(PhD)inChristina Weng(Chief Medical Officer)inNathan Wheeler(Chief Operating Officer)in

BoardCathy Friedman(Director)inDaniel Gil(CEO)

Co-investorsGV (Google Ventures)ARCH Venture PartnersHAWKTAILVisionary Ventures

Protego Biopharmaprotegobio.cominDec 2025 · $130M

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US

Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)

BoardTIM LOHOFF(Director)Edward Hurwitz(Director)

Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpact+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.